Prelude Capital Management’s Acrivon Therapeutics ACRV Stock Holding History

Prelude Capital Management’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$42.7K	Hold	24,015	–	–	﹤0.01%	1180
2026 Q1	$33.4K	Sell	24,015 -24,000	-50%	-$41.9K	﹤0.01%	1145
2025 Q4	$116K	Buy	+48,015	New	+$104K	0.01%	1164
2025 Q2	–	Sell	-13,067	Closed	-$26.5K	–	984
2025 Q1	$26.5K	Buy	+13,067	New	+$70.4K	﹤0.01%	1121
2024 Q4	–	Sell	-37,727	Closed	-$264K	–	1185
2024 Q3	$264K	Buy	+37,727	New	+$297K	0.02%	932
2024 Q2	–	Sell	-13,000	Closed	-$93K	–	1187
2024 Q1	$93K	Buy	+13,000	New	+$60.3K	﹤0.01%	1209

Other funds holding ACRV

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Prelude Capital Management's ACRV Position: Q2 2026 in Review

Prelude Capital Management held its Acrivon Therapeutics (ACRV) position steady in Q2 2026 at 24,015 shares worth $42.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1180.

Prelude Capital Management first reported a position in ACRV in Q1 2024 and has held it in 6 quarters since. The position peaked at $264K in Q3 2024. 46 funds tracked by Wall St. Rank hold ACRV as of Q2 2026.

Prelude Capital Management held 24,015 shares of Acrivon Therapeutics worth $42.7K as of Q2 2026.
Prelude Capital Management left its Acrivon Therapeutics share count unchanged in Q2 2026.
Acrivon Therapeutics made up ﹤0.01% of Prelude Capital Management's portfolio in Q2 2026, its #1180 holding.
Prelude Capital Management first reported a position in Acrivon Therapeutics in Q1 2024 and has held it in 6 quarters since.
Prelude Capital Management's Acrivon Therapeutics position peaked at $264K in Q3 2024.
46 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.